CA
NZ
UK
AU
IND
US
Retension sold 3,750,000 common shares at $12.00 each, for gross proceeds of $45.0 million before underwriting discounts and expenses. The underwriters hold a 30-day option on up to 562,500 more shares. The shares were expected to begin trading on the Nasdaq Capital Market on …
UBS kept its Buy rating and raised its price target to $26 from $23 on October 5, 2026, three days before the Pacira announcement. The price of USD 18.26 sits below that target. This is the firm's own view, not a forecast by this …
Deutsche Bank and Jefferies kept Buy ratings on July 24, with targets of $420 (from $405) and $410 (from $365). Citi kept Buy on August 3, raising its target to $412 from $400. UBS kept Buy on September 9 and raised its target to …
One large brokerage has acted since the August 6 second quarter results. Barclays raised its price target to $14 from $12 on October 6 and kept its Overweight rating. The USD 11.25 price sits below that target. This is the firm's own view, not …
Disc Medicine (NASDAQ:IRON) announced on Monday, October 19, 2026 that its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints. The disease causes painful sensitivity to light. Protoporphyrin IX, the compound that builds up in patients, fell 41.4% …
Moderna (NASDAQ:MRNA) fell 7.82% on October 16, 2026, among the largest S&P 500 decliners, behind Super Micro Computer and one other name. No filing, press release or analyst note dated that day explains the decline, according to the information reviewed. A German-language headline mentioned …
The most consequential news came from deals and clinical data. Several companies reported buyout terms, trial endpoints and regulatory timelines that will shape their next few quarters, although the share-price reactions did not always match the strength of the headlines.
● The consensus 12-month price target is $863.93, implying about 9.3% upside.
● The consensus 12-month price target is $571.46, implying about 14.3% upside.
● The consensus 12-month price target is $96.46, implying about 12.1% upside.
Please wait processing your request...